Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma
World Journal of Gastroenterology · 2023
DOI: 10.3748/wjg.v29.i2.286 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift World Journal of Gastroenterology, 2023. Verfasst von Simona Cernea und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department M3/Internal Medicine I, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Târgu Mureş 540139, Ro…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease, Liver Neoplasms, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 241 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Liver cancer is the sixth most commonly diagnosed cancer worldwide, with hepatocellular carcinoma (HCC) comprising most cases. Besides hepatitis B and C viral infections, heavy alcohol use, and nonalcoholic steatohepatitis (NASH)-associated advanced fibrosis/cirrhosis, several other risk factors for HCC have been identified (i.e. old age, obesity, insulin resistance, type 2 diabetes). These might in fact partially explain the occurrence of HCC in non-cirrhotic patients without viral infection. HCC surveillance through effective screening programs is still an unmet need for many nonalcoholic fatty liver disease (NAFLD) patients, and identification of pre-cirrhotic individuals who progress to HCC represents a substantial challenge in clinical practice at the moment. Patients with NASH-cirrhosis should undergo systematic HCC surveillance, while this might be considered in patients with advanced fibrosis based on individual risk assessment. In this context, interventions that potentially prevent NAFLD/ NASH-associated HCC are needed. This paper provided an overview of evidence related to lifestyle changes (i.e. weight loss, physical exercise, adherence to healthy dietary patterns, intake of certain dietary components, etc.) and pharmacological interventions that might play a protective role by targeting the underlying causative factors and pathogenetic mechanisms. However, well-designed prospective studies specifically dedicated to NAFLD/NASH patients are still needed to clarify the relationship with HCC risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department M3/Internal Medicine I, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Târgu Mureş 540139, Romania.
- Diabetes, Nutrition and Metabolic Diseases Outpatient Unit, Emergency County Clinical Hospital, Târgu Mureş 540136, Romania. simonacernea@yahoo.com.
- Department ME2/Internal Medicine VII, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureş, Târgu Mureş 540139, Romania.
- Gastroenterology Department, Mureș County Clinical Hospital, Târgu Mureș 540072, Romania.
Zitieren
APA
Cernea, S., & Onișor, D. (2023). Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v29.i2.286
Vancouver
Cernea S, Onișor D. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. World Journal of Gastroenterology. 2023. doi:10.3748/wjg.v29.i2.286
BibTeX
@article{Cernea2023,
author = {Cernea, Simona and Onișor, Danusia},
title = {Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma},
journal = {World Journal of Gastroenterology},
year = {2023},
doi = {10.3748/wjg.v29.i2.286}
}
EUVIMED